4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
IN8bio, Inc. (INAB) operates in the Biotechnology industry and is headquartered in New York, United States with about 18 employees. Its market capitalization is roughly $13 million. In the fiscal year ended 2025-12-31, INAB reported $0M in revenue and ($19M) in net income.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($20M) | ($30M) | ($30M) | ($28M) |
| Net Income | ($19M) | ($30M) | ($30M) | ($28M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($5M) | ($5M) | ($4M) | ($5M) | ($6M) | — |
| Net Income | ($5M) | ($5M) | ($4M) | ($5M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $32M | $21M | $34M | $33M | — |
| Total Liabilities | $5M | $6M | $9M | $10M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INAB viewer.
About TickerBase · Data methodology & sources